Immunohistochemistry for assessing toxicity and mechanism of action of anticancer drugs during preclinical trials. From theory to practice

Aim. To identify the most suitable pathogenetic mechanisms for in-depth study of the antitumor and antimetastatic effects of tested hybrid organotin compounds using the immunohistochemical approach.Materials and Methods. Here, we tested bis(3,5-di-tert-butyl-4-hydroxyphenylthiolate) dimethyltin (lab...

Full description

Saved in:
Bibliographic Details
Main Authors: M. A. Dodokhova, M. A. Akimenko, O. V. Voronova, M. S. Alkhusein-Kulyaginova, N. A. Kornienko, M. V. Gulyan, D. N. Gyulmamedov, M.-M. Kh. Alasheva, E. Sh. Kazimagomedova, D. B. Shpakovsky, E. R. Milaeva, I. M. Kotieva
Format: Article
Language:Russian
Published: Kemerovo State Medical University 2024-09-01
Series:Фундаментальная и клиническая медицина
Subjects:
Online Access:https://fcm.kemsmu.ru/jour/article/view/903
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849249106754535424
author M. A. Dodokhova
M. A. Akimenko
O. V. Voronova
M. S. Alkhusein-Kulyaginova
N. A. Kornienko
M. V. Gulyan
D. N. Gyulmamedov
M.-M. Kh. Alasheva
E. Sh. Kazimagomedova
D. B. Shpakovsky
E. R. Milaeva
I. M. Kotieva
author_facet M. A. Dodokhova
M. A. Akimenko
O. V. Voronova
M. S. Alkhusein-Kulyaginova
N. A. Kornienko
M. V. Gulyan
D. N. Gyulmamedov
M.-M. Kh. Alasheva
E. Sh. Kazimagomedova
D. B. Shpakovsky
E. R. Milaeva
I. M. Kotieva
author_sort M. A. Dodokhova
collection DOAJ
description Aim. To identify the most suitable pathogenetic mechanisms for in-depth study of the antitumor and antimetastatic effects of tested hybrid organotin compounds using the immunohistochemical approach.Materials and Methods. Here, we tested bis(3,5-di-tert-butyl-4-hydroxyphenylthiolate) dimethyltin (laboratory code Me-3), belonging to the class of hybrid organotin compounds, on 30 female C57Bl/6 mice using a universal model of transplantable tumors with spontaneous metastasis (B16 melanoma). 48 hours after tumor cell transplantation, we intraperitoneally administered Me-3 once daily to female C57Bl/6 mice for 10 days at a total dose (TD) of 375 mg/kg. For histological analysis, we used the primary tumor node of B16 melanoma. Immunophenotyping of B16 melanoma tissue samples was carried out using the polyclonal antibodies to transforming growth factor beta 1 (TGFβ-1), vascular endothelial growth factor A (VEGFA), Bcl2-associated X Protein (Bcl-2), cluster of differentiation 34 (CD34).Results. After the exposure to Me-3, we found a reduced immunohistochemical signal to TGF-β1 and Bcl-2 3 in the tumor tissue. Low doses of Me-3 have also impacted angiogenesis.Conclusion. Me-3 has a pro-apoptotic and anti-angiogenetic effects on B16 melanoma cells in C57Bl/6 mice.
format Article
id doaj-art-c22a6a9bfd4f416b8aa4576e31242467
institution Kabale University
issn 2500-0764
2542-0941
language Russian
publishDate 2024-09-01
publisher Kemerovo State Medical University
record_format Article
series Фундаментальная и клиническая медицина
spelling doaj-art-c22a6a9bfd4f416b8aa4576e312424672025-08-20T03:57:40ZrusKemerovo State Medical UniversityФундаментальная и клиническая медицина2500-07642542-09412024-09-0193748510.23946/2500-0764-2024-9-3-74-85442Immunohistochemistry for assessing toxicity and mechanism of action of anticancer drugs during preclinical trials. From theory to practiceM. A. Dodokhova0M. A. Akimenko1O. V. Voronova2M. S. Alkhusein-Kulyaginova3N. A. Kornienko4M. V. Gulyan5D. N. Gyulmamedov6M.-M. Kh. Alasheva7E. Sh. Kazimagomedova8D. B. Shpakovsky9E. R. Milaeva10I. M. Kotieva11Rostov State Medical UniversityRostov State Medical UniversityRegional Department of PathologyRostov State Medical UniversityRostov State Medical UniversityRostov State Medical UniversityRostov State Medical UniversityRostov State Medical UniversityRostov State Medical UniversityLomonosov Moscow State UniversityLomonosov Moscow State UniversityRostov State Medical UniversityAim. To identify the most suitable pathogenetic mechanisms for in-depth study of the antitumor and antimetastatic effects of tested hybrid organotin compounds using the immunohistochemical approach.Materials and Methods. Here, we tested bis(3,5-di-tert-butyl-4-hydroxyphenylthiolate) dimethyltin (laboratory code Me-3), belonging to the class of hybrid organotin compounds, on 30 female C57Bl/6 mice using a universal model of transplantable tumors with spontaneous metastasis (B16 melanoma). 48 hours after tumor cell transplantation, we intraperitoneally administered Me-3 once daily to female C57Bl/6 mice for 10 days at a total dose (TD) of 375 mg/kg. For histological analysis, we used the primary tumor node of B16 melanoma. Immunophenotyping of B16 melanoma tissue samples was carried out using the polyclonal antibodies to transforming growth factor beta 1 (TGFβ-1), vascular endothelial growth factor A (VEGFA), Bcl2-associated X Protein (Bcl-2), cluster of differentiation 34 (CD34).Results. After the exposure to Me-3, we found a reduced immunohistochemical signal to TGF-β1 and Bcl-2 3 in the tumor tissue. Low doses of Me-3 have also impacted angiogenesis.Conclusion. Me-3 has a pro-apoptotic and anti-angiogenetic effects on B16 melanoma cells in C57Bl/6 mice.https://fcm.kemsmu.ru/jour/article/view/903preclinical studiesantitumor drugsimmunohistochemistryangiogenesishybrid organotin compounds
spellingShingle M. A. Dodokhova
M. A. Akimenko
O. V. Voronova
M. S. Alkhusein-Kulyaginova
N. A. Kornienko
M. V. Gulyan
D. N. Gyulmamedov
M.-M. Kh. Alasheva
E. Sh. Kazimagomedova
D. B. Shpakovsky
E. R. Milaeva
I. M. Kotieva
Immunohistochemistry for assessing toxicity and mechanism of action of anticancer drugs during preclinical trials. From theory to practice
Фундаментальная и клиническая медицина
preclinical studies
antitumor drugs
immunohistochemistry
angiogenesis
hybrid organotin compounds
title Immunohistochemistry for assessing toxicity and mechanism of action of anticancer drugs during preclinical trials. From theory to practice
title_full Immunohistochemistry for assessing toxicity and mechanism of action of anticancer drugs during preclinical trials. From theory to practice
title_fullStr Immunohistochemistry for assessing toxicity and mechanism of action of anticancer drugs during preclinical trials. From theory to practice
title_full_unstemmed Immunohistochemistry for assessing toxicity and mechanism of action of anticancer drugs during preclinical trials. From theory to practice
title_short Immunohistochemistry for assessing toxicity and mechanism of action of anticancer drugs during preclinical trials. From theory to practice
title_sort immunohistochemistry for assessing toxicity and mechanism of action of anticancer drugs during preclinical trials from theory to practice
topic preclinical studies
antitumor drugs
immunohistochemistry
angiogenesis
hybrid organotin compounds
url https://fcm.kemsmu.ru/jour/article/view/903
work_keys_str_mv AT madodokhova immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice
AT maakimenko immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice
AT ovvoronova immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice
AT msalkhuseinkulyaginova immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice
AT nakornienko immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice
AT mvgulyan immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice
AT dngyulmamedov immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice
AT mmkhalasheva immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice
AT eshkazimagomedova immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice
AT dbshpakovsky immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice
AT ermilaeva immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice
AT imkotieva immunohistochemistryforassessingtoxicityandmechanismofactionofanticancerdrugsduringpreclinicaltrialsfromtheorytopractice